Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03878654 · ClinicalTrials.gov registry record · Phase 1
Trial of Tauroursodeoxycholic Acid (TUDCA) in Asthma
A Phase 1 study, sponsored by University of Vermont.
- Terminated
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT03878654 is a Phase 1 study that was terminated before completion, run by University of Vermont. The registered enrollment target is 11 participants.
The verdict
NCT03878654, a Phase 1 study, was terminated before completion, sponsored by University of Vermont.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
Asthma is a chronic lung disease that affects millions of people worldwide, including both children and adults. The cause of asthma is not known, but asthma is strongly associated with inflammation of the airways, often caused by allergies. In order to control this inflammation, most people with asthma are treated with inhaled medications that contain steroids. These medications do a good job of helping most people with asthma feel better. However, these medications are expensive, have side effects, and do not control symptoms in all people with asthma. Recently basic science research colleagues have shown that inflammation due to allergies can be reduced in experimental animals by a naturally occurring bile acid. Bile acids are chemicals made in the liver that are involved in maintaining healthy digestion of fat. Since bile acids are made by our bodies, they have become popular as over the counter supplements that are thought to be important in promoting a healthy liver and metabolism. Interestingly, other research has shown that bile acids may help patients with neurological disease and diabetes. Given all of this information, the investigators propose that a specific bile acid called tauroursodeoxycholic acid (TUDCA) may be helpful in patients with asthma. Before studying this in a clinical trial, the current study is designed to demonstrate that people with asthma can take TUDCA safely and that it doesn't hurt their asthma. The study will involve inviting 12 patients with mild asthma to take TUDCA daily for 12 weeks. During this time the investigators will closely monitor them for any side effects and check their blood and breathing capacity for any signs of detrimental effects. In addition, the investigators will collect cells that line the nose, which are thought to be similar to cells in the airways of the lungs, to see if TUDCA is having any beneficial effects on inflammation. In order to ensure the use of high quality TUDCA, which may or may not be true of
Interventions
- DRUG Tauroursodeoxycholic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2019-01-10 |
| Est. Completion | 2019-09-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03878654
The ClinicalTrials.gov registry entry for NCT03878654 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Vermont, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tauroursodeoxycholic Acid is the first listed.
NCT03878654 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03878654 about?
NCT03878654 is a clinical study titled "Trial of Tauroursodeoxycholic Acid (TUDCA) in Asthma". Asthma is a chronic lung disease that affects millions of people worldwide, including both children and adults. The cause of asthma is not known, but asthma is strongly associated with inflammation of the airways, often caused by allergies. In order to control this inflammation, most people with ast...
What is the current status of trial NCT03878654?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2019-01-10. Estimated completion is 2019-09-11.
What interventions are being tested in trial NCT03878654?
The interventions under investigation include: Tauroursodeoxycholic Acid (DRUG).
Who is sponsoring clinical trial NCT03878654?
This trial is sponsored by University of Vermont, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.